@dolcevita No. The number crunching boneheads don't distinguish...

@dolcevita

No. The number crunching boneheads don't distinguish between DRUG trials and STEM cells.

Since you are just an ordinary retail shareholder of MSB just like most are in HC, without any access to the inner workings of Teva, how could you keep accusing these professionals employed by Teva as "number crunching boneheads"?

It is delusional to assert that the outcome of stage 3 is a NO. If it were, the FDA would never agree to it.

Just because a trial has reached stage 3, it doesn't guarantee that the outcome will be a definite YES. There are plenty of stage 2 trials that were agreed by FDA to proceed to stage 3 that for various reasons never see the light of day.

It is delusional to confidently assert that the outcome of this stage 3 trial will definitely be a YES.

Stop pretending it's all logical outcomes. Teva has overreacted on the basis of their obviously poor decisionmaking on DRUG trials, and they've compounded this bad decisionmaking with a worse call.

Again, without access to the inner workings of Teva, you can't just accuse them of bad decision making. It is very arrogant to do so.

Quite frankly, I'm glad they did as we now have the IP clear of them. (Sweating on this a bit aren't you?)

Yup, just change your storyline to fit the latest development from MSB. If one day, Celgene and Teva sell all of their stake, or make an announcement that they will not be involved in any of MSB's products, will you also call Celgene's people stupid number crunching boneheads?